StockTipsArenaBeta

BUY Windlas Biotech Limited — Vishnu Kant Upadhyay, Master Capital Services

BUYWindlas Biotech Limited
Windlas Biotech share price target & all analyst calls

byVishnu Kant Upadhyay, Master Capital ServicesHorizon: NA (inferred Swing (≤2wk))17 Aug 2026via NDTV Profit

Entry₹943.05Inferred
Target₹1,100
Total upside +16.64% (call closed)
Stop loss₹880-6.69% risk
At expiry₹1,000.9528 Aug 2026, 3:30 pm
Expired+6.14%
Follow Vishnu Kant Upadhyay for new calls(13% target hit, 99 closed calls)Get alertsWatch WINDLAS for new buy/sell callsGet alertsSee 152 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 28 Aug 2026
1 supporting1 neutral0 opposing
Supports the BUY call (1)

Windlas Biotech Limited reported Q1 FY27 financial results with revenue of Rs 248 crores, an 18% YoY growth. Adjusted EBITDA grew 26% YoY to Rs 34 crores, and Adjusted PAT grew 37% YoY to Rs 25 crores

NSE · Press Release·10 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (1)

Windlas Biotech Limited has announced its financial results for the first quarter of the fiscal year 2027.

BSE · Company Update·10 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Windlas Biotech

All analyst calls on Windlas Biotech

More from Vishnu Kant Upadhyay, Master Capital Services

Every call and its outcome